Tofacitinib treatment in anti-glycyl-tRNA synthetase antibody interstitial lung disease - A case report.
Int J Rheum Dis
; 26(4): 781-785, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2304937
ABSTRACT
Anti-aminoacyl-transfer-RNA synthetase syndrome (ASS) related interstitial lung disease (ILD) is rarely presented initially alongside acute respiratory distress syndrome (ARDS), which in and of itself is a severe condition with a high mortality rate. Additionally, rapidly progressive change is not a common feature in ASS. Numerous case reports have described the efficacy which tofacitinib has on rapidly progressive ILD (RP-ILD). However, none have mentioned the use of tofacitinib in patients with impaired renal function. Herein, a case of ASS involving ILD is reported with the initial presentation of RP-ILD to ARDS being complicated by acute renal failure with an initial complete response to tofacitinib. Patients experiencing unexplained rapidly progressive interstitial pneumonia should be examined thoroughly for the diagnosis of ASS. Furthermore, tofacitinib can also be considered as a choice of treatment even in patients with impaired renal function.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Síndrome de Dificultad Respiratoria
/
Enfermedades Pulmonares Intersticiales
/
Aminoacil-ARNt Sintetasas
/
Glicina-ARNt Ligasa
/
Miositis
Tipo de estudio:
Reporte de caso
/
Estudios diagnósticos
Tópicos:
Covid persistente
Límite:
Animales
/
Humanos
Idioma:
Inglés
Revista:
Int J Rheum Dis
Asunto de la revista:
Reumatología
Año:
2023
Tipo del documento:
Artículo
País de afiliación:
1756-185X.14516
Similares
MEDLINE
...
LILACS
LIS